10X Genomics Inc
General ticker "TXG" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $1.8B
10X Genomics Inc does not follow the US Stock Market performance with the rate: -24.1%.
Estimated limits based on current volatility of 4.4%: low 13.14$, high 14.34$
Factors to consider:
- China accounted for 11.5% of revenue in the fiscal year ended 2022-12-31
- US accounted for 55.2% of revenue in the fiscal year ended 2022-12-31
- Current price 62.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [37.76$, 76.47$]
- 2024-12-30 to 2025-12-30 estimated range: [36.77$, 74.01$]
Financial Metrics affecting the TXG estimates:
- Negative: Non-GAAP EPS, $ of -1.89 <= 0.10
- Negative: Operating profit margin, % of -30.01 <= 1.03
- Negative: Operating cash flow per share per price, % of -0.26 <= 2.35
- Negative: negative Net income
- Negative: Industry operating profit margin (median), % of -12.70 <= 2.14
Short-term TXG quotes
Long-term TXG plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $490.49MM | $516.41MM | $618.73MM |
| Operating Expenses | $542.74MM | $684.35MM | $884.06MM |
| Operating Income | $-52.25MM | $-167.94MM | $-265.33MM |
| Non-Operating Income | $-1.46MM | $5.97MM | $16.57MM |
| Interest Expense | $0.87MM | $0.48MM | $0.03MM |
| R&D Expense | $211.75MM | $265.67MM | $270.33MM |
| Income(Loss) | $-53.72MM | $-161.97MM | $-248.76MM |
| Taxes | $4.51MM | $4.03MM | $6.34MM |
| Profit(Loss) | $-58.22MM | $-166.00MM | $-255.10MM |
| Stockholders Equity | $817.57MM | $805.74MM | $741.04MM |
| Inventory | $59.97MM | $81.63MM | $73.71MM |
| Assets | $1,018.83MM | $1,028.98MM | $965.14MM |
| Operating Cash Flow | $-21.37MM | $-33.61MM | $-15.20MM |
| Capital expenditure | $101.28MM | $131.66MM | $49.52MM |
| Investing Cash Flow | $-106.73MM | $-350.89MM | $133.49MM |
| Financing Cash Flow | $35.30MM | $15.82MM | $13.67MM |
| Earnings Per Share* | $-0.53 | $-1.46 | $-2.18 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.